NASDAQ · Drug Manufacturers - Specialty & Generic

GELS (GELS) Stock

$0.62 -6.94% NASDAQ: GELS Healthcare

Valuation

MetricValue
Price$0.62
Market Cap$5.65M
P/E Ratio—
P/B Ratio1.28
P/S Ratio111.13
EPS (TTM)$0.00
52-Week High$2.02
52-Week Low$0.39
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-42.99%
ROA-15.00%
ROCE-33.33%
Gross Margin100.00%
Operating Margin-33.18%
Net Margin-40.12%
Debt/Equity0.27
Current Ratio0.33

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-1.0M$-3.0M$-3.0M$-3.0M$-5.0M
Net Profit$-1.0M$-3.0M$-4.0M$-4.0M$-7.0M
EPS$-0.07$-0.36$-0.37$0.00$0.00
Op Margin—-2164.4%-3885.3%—-3317.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$24.0M$23.0M$22.0M$21.0M$21.0M
Total Liabilities$0$3.0M$4.0M$6.0M$6.0M
Cash$0$0$0$0$0
Borrowings$0$2.0M$2.0M$4.0M$4.0M

Latest News

Gelteq Provides Corporate Update: Launching Veterinary and Human Clinical Trials, Pharmaceutical Pipeline Expanding Across Multiple Programs GlobeNewswire · Jun 17, 2026 Top Premarket Gainers MT Newswires · Jun 15, 2026 Gelteq Successfully Completes Veterinary Palatability Trials with Kemin, Further Validating Gelteq® Technology for Animal Health Applications GlobeNewswire · Jun 12, 2026 Top Premarket Decliners MT Newswires · Jun 12, 2026 Gelteq Establishes Center of Excellence in China to Accelerate Product Development and Commercial Expansion GlobeNewswire · Jun 4, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$0$0$-2.0M$-1.0M$-6.0M
Investing Cash Flow$0$0$0$0$-1.0M
Financing Cash Flow$0$0$0$0$-2.0M
Net Cash Flow$0$0$0$0$0
Free Cash Flow$0$-2.0M$-2.0M$-1.0M$-6.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA-3.77
FCF Yield-33.49%
Quick Ratio0.27
Interest Coverage-2.50
Return 1Y-69.36%
Return 3Y—
Return 5Y—

Ownership

Insiders Held47.53%
Institutions Held0.58%
Institutions Float Held1.11%
Institutional HolderSharesReport Date
Wedbush Securities Inc20,0002026-03-31
Private Advisor Group, LLC16,6682026-03-31
Citadel Advisors Llc13,8302026-03-31
Two Sigma Investments, LP10,0522026-03-31
UBS Group AG1,8342026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AYTU $2.28 +3.23% -1.00 $24.49M 0.00%
BFRG $0.61 +4.04% -1.00 $7.11M 0.00%
BFRI $1.17 -4.88% -0.90 $14.98M 0.00%
BGLC $1.37 -9.27% -1.30 $2.76M 0.00%
COCP $0.92 +0.14% -1.46 $12.68M 0.00%

About GELS

GELS is led by CEO Nathan Jacob Givoni, publicly traded since 2024.

GELS stock trades at $0.62 with a market capitalization of $5.65M. The stock is valued at price-to-book of 1.28, price-to-sales of 111.13. Over the past 52 weeks the stock has ranged between $0.39 and $2.02, and currently trades 69.3% below its 52-week high.

On profitability, GELS generates a return on equity (ROE) of -42.99%, return on capital employed of -33.33%, an operating margin of -33.18%, a net profit margin of -40.12%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides